Typhoid conjugate Vaccine

Phase 2Vaccine

Sanofi

Typhoid conjugate Vaccine is one of 28 biologic programs targeting Malaria. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalariaRecruiting

MalariaPhase 2

Recruiting

Competition

Competitive Landscape

94 competitors in Malaria

#DrugCompanyPhaseTrials

Dihydroartemisinin-Piperaquine

GSK

Phase 3

51 2

Rabies Vaccine

Novartis

Phase 3

9 3

YF-Vax

Sanofi

Phase 3

1 4

Krintafel

GGlaxo Dba Glaxosmithkline

Phase 3

4 5

Artemether-Lumefantrine (AL)

Novartis

Phase 3

11 6

Artesunate-Amodiaquine

Sanofi

Phase 3

19 7

Pfspz Challenge

Merck & Co.

Phase 2

11 8

R21/matrix-M

UUniversity of Oxford

Phase 3

4 9

Pyramax

SShin Poong Pharmaceutical Co. Ltd.

Phase 3

2 10

Biltricide

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Malaria

NCT06879327

Q1 2029

Post-ApprovalNot yet recruiting

Malnutrition

NCT06817421

Clinical

Trials by Indication[1]

Vaccine2 trials

Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India

Completed·SStanford University··NCT03554213·17,292 enrolled

Vellore Typhoid Vaccine Impact Trial

Completed·—·Phase 4·NCT05500482·72,400 enrolled

Malnutrition1 trial

Opportunistic Pneumococcal Immunisation Trial in MALnutrition

Not yet recruiting·NNick Fancourt·Phase 4·NCT06817421·214 enrolled

Pediatric1 trial

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Completed· Sanofi logo

Sanofi·Phase 3·NCT05794230·1,528 enrolled

Malaria1 trial

Infant Malaria Vaccine Schedule Optimization

Recruiting·PPATH·Phase 2·NCT06879327·1,200 enrolled

Unspecified1 trial

Co-administration Study of OCV, TCV and MR

Unknown status·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 3·NCT05771779·2,117 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Typhoid conjugate Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Typhoid conjugate Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Typhoid conjugate Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: Sanofi

Typhoid conjugate Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q1 2029

Trials by Indication[1]

Vaccine2 trials

Malnutrition1 trial

Pediatric1 trial

Malaria1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News